title: [Clinical Study to Determine the Dose Intensity of BEP Chemotherapy for Ovarian Malignant Germ Cell Tumors].
abstract: A standard regimen for ovarian malignant germ cell tumors is bleomycin, etoposide, cisplatin(BEP)chemotherapy. Adherence to a treatment schedule of every 21 days has been reported to be important. However, the incidence of febrile neutropenia( FN)and the optimaluse of granulocyte-colony stimulating factor(G-CSF)are unclear because of the low incidence of ovarian malignant germ cell tumors. We experienced 2 cases of ovarian malignant germ cell tumors that received BEP therapy after fertility-conserving surgery. In 1 case, we delayed drug administration in the first cycle because of FN. However, in order to maintain dose intensity(DI), we performed chemotherapy every 21 days by shortening the rest period. Myelosuppression may be severe in the first cycle of BEP therapy; however, it may be possible to adhere to the treatment schedule by using primary prophylactic administration of G-CSF.
authors.affiliation: Dept. of Obstetrics and Gynecology, Hiroshima Prefectural Hospital.
authors.forename: Shinya
authors.initials: S
authors.lastname: Kusumoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Naito
authors.forename: Kunitomo
authors.initials: K
authors.lastname: Imazu
authors.forename: Itsuka
authors.initials: I
authors.lastname: Kai
authors.forename: Aki
authors.initials: A
authors.lastname: Hamasaki
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Kazusa
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Miho
authors.initials: M
authors.lastname: Kodama
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kumagai
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ueda
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin